Information disclosure. Our goal is to present products and services that we think you may find interesting and useful. If you purchase them, the Entrepreneur may receive a small share of the proceeds from the sale from our channel partners.
As the 70+ million Baby Boomers age, there is a huge opportunity for medical companies to help restore and preserve their bodies. Enter Monogram Orthopedicsa company reimagining the knee replacement surgery process with robotic surgeons and patient-specific implants.
With increasing demand for more and better knee replacement surgeries, the industry is projected to reach $26 billion by 2027, and Monogram is one of the few who goes to meet him. They not only developed a new way of performing joint surgery, but also applied a new approach to the joints themselves.
Here’s what makes Monogram such an interesting startup and why investors this possibility should be considered.
How the world can benefit from robotic joint surgery.
About 40 years old innovative joint replacement stuck in standby mode. Market leaders continue to use the same hacksaws, fixtures and bone cement, not to mention the same inaccurate surgeries with long recovery times.
But they don’t maintain the status quo “because it works.” As it turns out, 36% of people end up wishing they had never had joint surgery. The market simply hasn’t been able to offer them anything better than regular replacements that wear out over time and potentially lead to more joint problems due to poor fit.
This is problem Monogram came to the solution with the help of ultra-precise robotic joint surgery and 3D printed individual joints. The best instruments and knee replacements have the potential to give each patient a custom fit to prevent wobbling and prolong life.
The Monogram team and its robots have already shown successful demos in front of thousands of online viewers in their own Monogram studio. modern cadaver laboratory. And the company is working to capture a significant part of this market in the future.
Monogram’s market opportunity is estimated at $19.4 billion.
To put things in perspective, there is 933,000 knee replacements every year, and 100,000 of them fail. This is partly because 92% of them use cement with conventional implants that are not optimized for each patient. Not to mention the risk of human error.
One reason for this is that only four major competitors control 82% of the joint replacement market: Stryker, Zimmer, Smith & Nephew, and DepuySynthes. They will have to adapt at some point as up to 50% of all joint replacements are predicted to be robotic by 2030. But the company believes that with 20 patent applications and active development, the company can have a significant first-mover advantage.
Here’s what’s next for Monogram and how you can get involved.
Proposed Monogram listing on NASDAQ.
The company intends to expand its presence through direct NASDAQ listing.
They start with Reg A Investment Opportunity where the shares would trade at a fixed price of $7.25 per share prior to the proposed listing, after which they would be freely traded on the market.
This basically means that Entrepreneur readers have the opportunity to invest in the company at a fixed price prior to the proposed public listing. This type of investment used to be limited to big banks and venture capitalists, but crowdfunding allows retail investors to get into companies like Monogram before they are listed on a public exchange.
Learn more about becoming a Monogram shareholder before they go public.
Disclosure: This is a paid advertisement for Monogram Orthopedics’ A+ offering. Find out more at invest.monogramortopedics.com/disclaimer
The entrepreneur may receive monetary compensation from the issuer or its agency for making public the issuer’s offer of securities. The Entrepreneur and the issuer of this offer make no promises, representations, guarantees or guarantees that any services will bring profit or result in no loss.